FLAMEK Corporation headquarters are located in Tartu, Estonia.
FLAMEK is focused on developing novel, effective, safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes. It is envisioned that FLAMEK products will have significant market potential. The products are protected by an aggressive patent program.
FLAMEK is focused on early-stage drug research and development and commercialization of these innovative therapeutic products. The Company's technology platforms focus on transdermal drug delivery. Products are aimed at expanding treatment options in acute postoperative and chronic neuropathic pain, rheumatology and dermatology.
FLAMEK is also offering you clinical research services from phase I studies to phase IV and all the way to the maintenance of marketing authorization.